Международный эндокринологический журнал Том 22, №4, 2026

Основним чинником у патогенезі серцево-судинних захворювань (ССЗ) при цукровому діабеті (ЦД) 2-го типу є синергетична взаємодія між оксидативним стресом (ОС), спричиненим гіперглікемією, та хронічним запаленням низької інтенсивності (ХЗНІ). Метаболічна дисрегуляція, мітохондріальна дисфункція, стрес ендоплазматичного ретикулуму та епігенетичне перепрограмування взаємодіють і зумовлюють активацію ОС та каскадів ХЗНІ. Вторинні метаболіти рослинного походження, особливо флавоноїди, на відміну від традиційних синтетичних препаратів із вузьконаправленою дією, демонструють синергічний вплив на кілька біологічних мішеней. Вони здатні одночасно модулювати низку ключових патофізіологічних процесів, що сприяє відновленню окисно-відновної рівноваги та пригніченню запальних реакцій. Це сприяє поліпшенню функціонування судин і уповільненню розвитку ССЗ при ЦД 2-го типу. Попри перспективні експериментальні результати, що свідчать про потенційно позитивний вплив кверцетину на стан серцево-судинної системи при ЦД 2-го типу, дані клінічних досліджень залишаються суперечливими. Це переважно пов’язано з обмеженою кількістю рандомізованих клінічних досліджень (РКД), спрямованих на вивчення ефектів флавоноїду та його похідних. З огляду на це необхідно провести РКД із більш досконалим дизай­ном і розширеним обсягом вибірки, що дозволить випробувати різні концентрації кверцетину. Такий підхід сприятиме глибшому розкриттю його терапевтичного потенціалу в лікуванні ССЗ у пацієнтів із ЦД 2-го типу. Основною метою огляду є аналіз ролі кверцетину у лікуванні ССЗ у пацієнтів із ЦД 2-го типу. Додатково висвітлюються сучасні тенденції та визначаються перспективні напрями для майбутніх досліджень у цій галузі. Пошук проводився в Scopus, Science Direct (від Elsevier) і PubMed, включно з базами даних Medline. Використані ключові слова «цукровий діабет 2-го типу», «серцево-судинні захворювання», «кверцетин». Для виявлення результатів досліджень, які не вдалося знайти під час онлайн-пошуку, використовувався ручний пошук бібліографії публікацій.

The main factor in the pathogenesis of cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM) is the synergistic interaction between oxidative stress caused by hyperglycemia and low-grade chronic inflammation. Metabolic dysregulation, mitochondrial dysfunction, endoplasmic reticulum stress, and epigenetic reprogramming interact and cause the activation of oxidative stress and low-grade chronic inflammation cascades. Secondary metabolites of plant origin, especially flavonoids, unlike traditional synthetic drugs with narrow-targeted action, demonstrate a synergistic effect on several biological targets. They are capable of simultaneously modulating a number of key pathophy­siological processes, which contributes to the restoration of redox balance and suppression of inflammatory reactions. As a result, this contributes to improved vascular function and slows down the development of CVD in T2DM. Despite promising experimental results indicating the potentially positive effect of quercetin on the cardiovascular system in T2DM, clinical trial data remain controversial. This is mainly due to the limited number of randomized clinical trials aimed at studying the effects of flavonoids and their derivatives. In view of this, it is necessary to conduct randomized clinical trials with a more sophisticated design and an expanded sample size, which will allow testing different concentrations of quercetin. This approach will contribute to a deeper understanding of its therapeutic potential in the treatment of CVD in patients with T2DM. The main objective of the review is to analyze the role of quercetin in the treatment of CVD in patients with T2DM. In addition, current trends are highlighted, and promising directions for future research in this area are identified. The search was conducted in Scopus, ScienceDirect (from Elsevier), and PubMed, including MEDLINE databases. The keywords “type 2 diabetes mellitus”, “cardiovascular disease”, and “quercetin” were used. To identify research results that could not be found during the online search, a manual search of the bibliography of publications was used.

цукровий діабет 2-го типу; серцево-судинні захворювання; кверцетин; огляд літератури

type 2 diabetes mellitus; cardiovascular disease; quercetin; literature review

1. Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. Circ Res. 2020 May 22;126(11):1501-1525. doi: 10.1161/CIRCRESAHA.120.315913.
2. Serhiyenko VA, Serhiyenko AA. Diabetic Cardiac Autonomic Neuropathy. In: Saldaña JR, editor. Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues. Basel: Sprin–ger, Cham. Springer Nature Switzerland AG; 2019. 825-850 рр. doi: 10.1007/978-3-030-11815-0_53.
3. Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Features of Circadian Rhythms of Heart Rate Variability, Arterial Stiffness and Outpatient Monitoring of Blood Pressure in Diabetes Mellitus: Data, Mechanisms and Consequences. In: Sinha RP, editor. Circadian Rhythms and Their Importance. New York, NY: Nova Science Publishers; 2022. 279-341 pp. doi: 10.52305/GXME8274.
4. Liu S, Liu J, Wang Y, Deng F, Deng Z. Oxidative Stress: Signaling Pathways, Biological Functions, and Disease. MedComm (2020). 2025 Jul 1;6(7):e70268. doi: 10.1002/mco2.70268.
5. Liu J, Li K, Yi Z, Saqirile, Wang C, Yang R. Oxidative-Inflammatory Crosstalk and Multi-Target Natural Agents: Decoding Diabetic Vascular Complications. Curr Issues Mol Biol. 2025 Aug 4;47(8):614. doi: 10.3390/cimb47080614.
6. Yang W, Guo J, Song J, Guo S. Studies of Foxo1 over the Past 25 Years: Mechanisms of Insulin Resistance and Glucose Dysregulation. Cells. 2026 Jan 8;15(2):109. doi: 10.3390/cells15020109.
7. Blahova J, Martiniakova M, Babikova M, Kovacova V, Mondockova V, Omelka R. Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus. Pharmaceuticals (Basel). 2021 Aug 17;14(8):806. doi: 10.3390/ph14080806.
8. Serhiyenko VA, Serhiyenko LM, Sehin VB, Serhiyenko AA. Pathophysiological and clinical aspects of the circadian rhythm of arterial stiffness in diabetes mellitus: A minireview. Endocr Regul. 2022 Oct 20;56(4):284-294. doi: 10.2478/enr-2022-0031.
9. Aguilar M, Alberti KGMM, Amiel SA, et al. Leitfaden zu typ-2-diabetes mellitus / Guide for type 2 diabetes mellitus (Review). Diabetes und Stoffwechsel. 2000 Mar 20;9(2):104-136. ISSN: 09420037.
10. Gieroba B, Kryska A, Sroka-Bartnicka A. Type 2 diabetes mellitus — conventional therapies and future perspectives in innovative treatment. Biochem Biophys Rep. 2025 May 2;42:102037. doi: 10.1016/j.bbrep.2025.102037.
11. Luna-Marco C, Iannantuoni F, Hermo-Argibay A, et al. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor ago–nists through effects on mitochondrial function and oxidative stress. Free Radic Biol Med. 2024 Mar;213:19-35. doi: 10.1016/j.freeradbiomed.2024.01.015.
12. Khattab E, Kyriakou M, Leonidou E, et al. Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy-Challenges and Prospectives. Pharmaceuticals (Basel). 2025 Jan 20;18(1):134. doi: 10.3390/ph18010134.
13. Liu X, Liang Q, Qin Y, Chen Z, Yue R. Advances and Perspectives on the Anti-Fibrotic Mechanisms of the Quercetin. Am J Chin Med. 2025;53(5):1411-1440. doi: 10.1142/S0192415X25500545.
14. Saad AM, Mohammed DM, Alkafaas SS, et al. Dietary polyphenols and human health: sources, biological activities, nutritional and immunological aspects, and bioavailability — a comprehensive review. Front Immunol. 2025 Nov 3;16:1653378. doi: 10.3389/fimmu.2025.1653378.
15. Ciupei D, Colişar A, Leopold L, Stănilă A, Diaconeasa ZM. Polyphenols: From Classification to Therapeutic Potential and Bioavailability. Foods. 2024 Dec 20;13(24):4131. doi: 10.3390/foods13244131.
16. Caiati C, Jirillo E. Cellular and Molecular Bases for the Application of Polyphenols in the Prevention and Treatment of Cardiovascular Disease. Diseases. 2025 Jul 15;13(7):221. doi: 10.3390/diseases13070221.
17. Clemente-Suárez VJ, Martín-Rodríguez A, Beltrán-Velasco AI, et al. Functional and Therapeutic Roles of Plant-Derived Antioxidants in Type 2 Diabetes Mellitus: Mechanisms, Challenges, and Considerations for Special Populations. Antioxidants (Basel). 2025 Jun 13;14(6):725. doi: 10.3390/antiox14060725.
18. González P, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. Int J Mol Sci. 2023 May 27;24(11):9352. doi: 10.3390/ijms24119352.
19. Hussain A. Chronic hyperglycemia and cardiovascular dysfunction: an in-depth exploration of metabolic and cellular pathways in type 2 diabetes mellitus. Cardiovasc Diabetol Endocrinol Rep. 2025 Dec 12;11(1):39. doi: 10.1186/s40842-025-00247-3.
20. Roy B. Pathophysiological Mechanisms of Diabetes-Induced Macrovascular and Microvascular Complications: The Role of Oxi–dative Stress. Med Sci (Basel). 2025 Jul 2;13(3):87. doi: 10.3390/medsci13030087.
21. Andrés CMC, Pérez de la Lastra JM, Andrés Juan C, Plou FJ, Pérez-Lebeña E. Superoxide Anion Chemistry — Its Role at the Core of the Innate Immunity. Int J Mol Sci. 2023 Jan 17;24(3):1841. doi: 10.3390/ijms24031841.
22. Jomova K, Raptova R, Alomar SY, et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. Arch Toxicol. 2023 Oct;97(10):2499-2574. doi: 10.1007/s00204-023-03562-9.
23. Serhiyenko VA, Serhiyenko LM, Sehin VB, Serhiyenko AA. Effect of alpha-lipoic acid on arterial stiffness parameters in type 2 diabetes mellitus patients with cardiac autonomic neuropathy. Endocr Regul. 2021;55(4):224-233. doi: 10.2478/enr-2021-0024.
24. Moratilla-Rivera I, Sánchez M, Valdés-González JA, Gómez-Serranillos MP. Natural Products as Modulators of Nrf2 Signaling Pathway in Neuroprotection. Int J Mol Sci. 2023 Feb 13;24(4):3748. doi: 10.3390/ijms24043748.
25. Buttari B, Tramutola A, Rojo AI, et al. Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2. Biomolecules. 2025 Jan 13;15(1):113. doi: 10.3390/biom15010113.
26. Albert-Garay JS, Riesgo-Escovar JR, Salceda R. High glucose concentrations induce oxidative stress by inhibiting Nrf2 expression in rat Müller retinal cells in vitro. Sci Rep. 2022 Jan 24;12(1):1261. doi: 10.1038/s41598-022-05284-x.
27. Neagu M, Constantin C, Surcel M, et al. Diabetic neuropathy: A NRF2 disease? J Diabetes. 2024 Sep;16(9):e13524. doi: 10.1111/1753-0407.13524.
28. Xiao K, Liu C, Tu Z, et al. Activation of the NF-κB and MAPK Signaling Pathways Contributes to the Inflammatory Respon–ses, but Not Cell Injury, in IPEC-1 Cells Challenged with Hydrogen Peroxide. Oxid Med Cell Longev. 2020 Jan 21;2020:5803639. doi: 10.1155/2020/5803639.
29. Bruzeau C, Cook-Moreau J, Pinaud E, Le Noir S. Contribution of Immunoglobulin Enhancers to B Cell Nuclear Organization. Front Immunol. 2022 Jun 24;13:877930. doi: 10.3389/fimmu.2022.877930.
30. Desideri E, Castelli S, Ciriolo MR. MAPK Signaling in the Interplay Between Oxidative Stress and Autophagy. Antioxidants (Basel). 2025 May 30;14(6):662. doi: 10.3390/antiox14060662.
31. Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Omega-3 polyunsaturated fatty acids in the treatment of diabetic cardiovascular autonomic neuropathy: A review. In: Moore SJ, editor. Omega-3: Dietary sources, biochemistry and impact on human health. New York, NY: Nova Science Publishers; 2017. 79-154 pp.
32. Mao H, Zhao X, Sun SC. NF-κB in inflammation and cancer. Cell Mol Immunol. 2025 Aug;22(8):811-839. doi: 10.1038/s41423-025-01310-w.
33. Serhiyenko V, Sehin V, Serhiyenko A. Vitamin B12, depression and type 2 diabetes (literature review). Problems of Endocrine Pathology (Ukraine). 2025;82(4):54-69. Ukrainian. doi: 10.21856/j-PEP.2025.4.07.
34. Shashikanth N, Alaidi O, Basa L, Taank S, Rao R, Seetharaman J. Role of C-Jun N-Terminal Kinases on a Stressed Epithelium: Time for Testing Isoform Specificity. Biology (Basel). 2025 Jun 3;14(6):649. doi: 10.3390/biology14060649.
35. Chu CT, Uruno A, Katsuoka F, Yamamoto M. Role of NRF2 in Pathogenesis of Alzheimer’s Disease. Antioxidants (Basel). 2024 Dec 13;13(12):1529. doi: 10.3390/antiox13121529.
36. Serhiyenko VA, Sehin VB, Serhiyenko LM, Serhiyenko AA. Post-traumatic stress disorder, metabolic syndrome, and chronic low-grade inflammation: A narrative review. Problems of Endocrine Pathology (Ukraine). 2024 Mar 14;81(1):77-83. Ukrainian. doi: 10.21856/j-PEP.2024.1.10.
37. Wang N, Zhang C. Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease. Antioxidants (Basel). 2024 Apr 12;13(4):455. doi: 10.3390/antiox13040455.
38. Li R, Yan X, Zhao Y, et al. Oxidative Stress Induced by Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) Dysfunction Aggravates Chronic Inflammation Through the NAD+/SIRT3 Axis and Promotes Renal Injury in Diabetes. Antioxidants (Basel). 2025 Feb 25;14(3):267. doi: 10.3390/antiox14030267.
39. Lemanowicz J, Gawlińska K, Jaskulska I, Jaskulski D, Sar M. Flavonoids in Plants and Human Health: From Biosynthesis to Neurodevelopmental and Neurodegenerative Disorders. Molecules. 2025 Dec 24;31(1):66. doi: 10.3390/molecules31010066.
40. Chen S, Wang X, Cheng Y, Gao H, Chen X. A Review of Classification, Biosynthesis, Biological Activities and Potential Applications of Flavonoids. Molecules. 2023 Jun 25;28(13):4982. doi: 10.3390/molecules28134982.
41. Vollmannová A, Bojňanská T, Musilová J, Lidiková J, Cifrová M. Quercetin as one of the most abundant represented biological valuable plant components with remarkable chemoprotective effects — A review. Heliyon. 2024 Jun 20;10(12):e33342. doi: 10.1016/j.heliyon.2024.e33342.
42. Kábelová A, Malínská H, Marková I, Hűttl M, Chylíková B, Šeda O. Quercetin supplementation alters adipose tissue and hepatic transcriptomes and ameliorates adiposity, dyslipidemia, and glucose intolerance in adult male rats. Front Nutr. 2022 Sep 29;9:952065. doi: 10.3389/fnut.2022.952065.
43. Yang D, Wang T, Long M, Li P. Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medi–cine. Oxid Med Cell Longev. 2020 Dec 30;2020:8825387. doi: 10.1155/2020/8825387.
44. Al-Zharani M, Mubarak M, Rudayni HA, Al-Doaiss AA, Abd-Elwahab MM, Al-Eissa MS. Quercetin as a Dietary Supplementary Flavonoid Alleviates the Oxidative Stress Induced by Lead Toxicity in Male Wistar Rats. Nutrients. 2023 Apr 14;15(8):1888. doi: 10.3390/nu15081888.
45. Rarinca V, Nicoara MN, Ureche D, Ciobica A. Exploitation of Quercetin’s Antioxidative Properties in Potential Alternative Therapeutic Options for Neurodegenerative Diseases. Antioxidants (Basel). 2023 Jul 13;12(7):1418. doi: 10.3390/antiox12071418.
46. Chaudhary P, Janmeda P, Docea AO, et al. Oxidative stress, free radicals and antioxidants: potential crosstalk in the pathophysio–logy of human diseases. Front Chem. 2023 May 10;11:1158198. doi: 10.3389/fchem.2023.1158198.
47. Li Z, Li Y, Jiang T, Wang Y, Li C, He Z. Quercetin and Its Metabolites: Mechanistic Insights as the Basis of Their Therapeutic Potential in NAFLD and HCC. Molecules. 2025 Nov 17;30(22):4441. doi: 10.3390/molecules30224441.
48. Qi W, Qi W, Xiong D, Long M. Quercetin: Its Antioxidant Mechanism, Antibacterial Properties and Potential Application in Prevention and Control of Toxipathy. Molecules. 2022 Oct 3;27(19):6545. doi: 10.3390/molecules27196545.
49. Zhang W, Zheng Y, Yan F, Dong M, Ren Y. Research progress of quercetin in cardiovascular disease. Front Cardiovasc Med. 2023 Nov 16;10:1203713. doi: 10.3389/fcvm.2023.1203713.
50. Alharbi HOA, Alshebremi M, Babiker AY, Rahmani AH. The Role of Quercetin, a Flavonoid in the Management of Pathogenesis Through Regulation of Oxidative Stress, Inflammation, and Biologi–cal Activities. Biomolecules. 2025 Jan 20;15(1):151. doi: 10.3390/biom15010151.
51. Li Y, Man M, Tian Y, et al. Quercetin protects against neuronal toxicity by activating the PI3K/Akt/GSK-3β pathway in vivo models of MPTP-induced Parkinson’s disease. Inflammopharmacol. 2025;33:4063-4076. doi: 10.1007/s10787-025-01712-2.
52. Zhang Z, Yi P, Yi M, et al. Protective Effect of Quercetin against H2O2-Induced Oxidative Damage in PC-12 Cells: Comprehensive Analysis of a lncRNA-Associated ceRNA Network. Oxid Med Cell Longev. 2020 Dec 1;2020:6038919. doi: 10.1155/2020/6038919.
53. Peng C, Li H, Mao Q, et al. Quercetin inhibits hydrogen peroxide-induced cleavage of heat shock protein 90 to prevent glutathione peroxidase 4 degradation via chaperone-mediated autophagy. Phytomedicine. 2025 Jan;136:156286. doi: 10.1016/j.phymed.2024.156286.
54. Amić A, Mastiľák Cagardová D. A DFT Study on the Kinetics of HOO•, CH3OO•, and O2•- Scavenging by Quercetin and Flavonoid Catecholic Metabolites. Antioxidants (Basel). 2023 May 25;12(6):1154. doi: 10.3390/antiox12061154.
55. Anwar S, Sarwar T, Khan AA, Rahmani AH. Therapeutic Applications and Mechanisms of Superoxide Dismutase (SOD) in Different Pathogenesis. Biomolecules. 2025 Aug 5;15(8):1130. doi: 10.3390/biom15081130.
56. Albadrani GM, BinMowyna MN, Bin-Jumah MN, El-Aka–bawy G, Aldera H, Al-Farga AM. Quercetin prevents myocardial infarction adverse remodeling in rats by attenuating TGF-β1/Smad3 signaling: Different mechanisms of action. Saudi J Biol Sci. 2021 May;28(5):2772-2782. doi: 10.1016/j.sjbs.2021.02.007.
57. Liu L, Zhao Q, Huang J, Lei S. Cadmium-Induced Hepatotoxicity in Mice — Prophylactic Supplementation of Quercetin Exerts Hepatoprotective Effect by Modulating PI3K/Akt/NF-kappaB Signa–ling Pathway. Physiol Res. 2024 Nov 12;73(5):703-716. doi: 10.33549/physiolres.935252.
58. Xiong F, Zhang Y, Li T, et al. A detailed overview of quercetin: implications for cell death and liver fibrosis mechanisms. Front Pharmacol. 2024 May 23;15:1389179. doi: 10.3389/fphar.2024.1389179.
59. Jomova K, Alomar SY, Valko R, Nepovimova E, Kuca K, Valko M. The role of redox-active iron, copper, manganese, and redox-inactive zinc in toxicity, oxidative stress, and human diseases. EXCLI J. 2025 Jul 25;24:880-954. doi: 10.17179/excli2025-8449.
60. Jiang H, Zhou Y, Nabavi SM, et al. Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis. Front Cardiovasc Med. 2022 Jun 1;9:925923. doi: 10.3389/fcvm.2022.925923.
61. Guo J, Du L. An update on ox-LDL-inducing vascular smooth muscle cell-derived foam cells in atherosclerosis. Front Cell Dev Biol. 2024 Oct 25;12:1481505. doi: 10.3389/fcell.2024.1481505.
62. Serhiyenkо VA, Chemerys OM, Pankiv VI, Serhiyenko AA. Post-traumatic stress disorder, metabolic syndrome, diabetic distress, and vitamin B1/benfotiamine. International Neurological Journal (Ukraine). 2025;21(1):96-107. Ukrainian. doi: 10.22141/2224 0713.21.1.2025.1157.
63. Luo M, Zhao F, Cheng H, Su M, Wang Y. Macrophage polarization: an important role in inflammatory diseases. Front Immunol. 2024 Apr 10;15:1352946. doi: 10.3389/fimmu.2024.1352946.
64. Downton P, Bagnall JS, England H, et al. Overexpression of IκBα modulates NF-κB activation of inflammatory target gene expression. Front Mol Biosci. 2023 May 9;10:1187187. doi: 10.3389/fmolb.2023.1187187.
65. Serhiyenkо VA, Chemerys OM, Pankiv VI, Serhiyenko AA. Type 2 diabetes mellitus, cerebral small vessel disease and depressive disorders. International Neurological Journal (Ukraine). 2025 May 20;21(3):226-237. Ukrainian. doi: 10.22141/2224 0713.21.3.2025.1178.
66. Serhiyenko VA, Sehin VB, Serhiyenko LM, Serhiyenko AA. Post-traumatic stress disorder, metabolic syndrome, and the autonomic nervous system. Endokrynologia. 2023 Dec;28(4):377-392. Ukrainian. doi: 10.31793/1680-1466.2023.28-4.377.
67. Kim M, An J, Shin SA, et al. Anti-inflammatory effects of TP1 in LPS-induced Raw264.7 macrophages. Appl Biol Chem. 2024;67:16. doi: 10.1186/s13765-024-00873-y.
68. Aggarwal D, Chaudhary M, Mandotra SK, et al. Anti-inflammatory potential of quercetin: From chemistry and mechanistic insight to nanoformulations. Curr Res Pharmacol Drug Discov. 2025 Mar 18;8:100217. doi: 10.1016/j.crphar.2025.100217.
69. Ozorowski M, Wiciński M, Kuźmiński O, et al. The Effects of Quercetin on Vascular Endothelium, Inflammation, Cardiovascular Disease and Lipid Metabolism — A Review. Nutrients. 2025 May 3;17(9):1579. doi: 10.3390/nu17091579.
70. Frenț OD, Stefan L, Morgovan CM, et al. A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability. Int J Mol Sci. 2024 Nov 11;25(22):12091. doi: 10.3390/ijms252212091.
71. Luo J, Luo J, Fang Z, Fu Y, Xu BB. Insights Into Effects of Natural Bioactive Components on Inflammatory Diseases in Respiratory Tract. Phytother Res. 2025 Sep;39(9):4199-4229. doi: 10.1002/ptr.8367.
72. Aghababaei F, Hadidi M. Recent Advances in Potential Health Benefits of Quercetin. Pharmaceuticals (Basel). 2023 Jul 18;16(7):1020. doi: 10.3390/ph16071020.
73. Al-Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, Al-Mssallem MQ. Flavonoids as Potential Anti-Inflammatory Molecules: A Review. Molecules. 2022 May 2;27(9):2901. doi: 10.3390/molecules27092901.
74. Nasrollahi Z, ShahaniPour K, Monajemi R, Ahadi AM. Effect of quercetin and Abelmoschus esculentus (L.) Moench on li–pids meta–bolism and blood glucose through AMPK-α in diabetic rats (HFD/STZ). J Food Biochem. 2022 Dec;46(12):e14506. doi: 10.1111/jfbc.14506.
75. Niziński P, Hawrył A, Polak P, et al. Potential of Quercetin as a Promising Therapeutic Agent Against Type 2 Diabetes. Molecules. 2025 Jul 24;30(15):3096. doi: 10.3390/molecules30153096.
76. Sharebiani H, Mokaram M, Mirghani M, Fazeli B, Stanek A. The effects of antioxidant supplementation on the pathologic mechanisms of metabolic syndrome and cardiovascular disease development. Nutrients. 2024 May 27;16(11):1641. doi: 10.3390/nu16111641.
77. Jiang M, Wang K, Huang Y, et al. Quercetin Alleviates Lipopolysaccharide-Induced Cell Oxidative Stress and Inflammatory Responses via Regulation of the TLR4-NF-κB Signaling Pathway in Bovine Rumen Epithelial Cells. Toxins (Basel). 2023 Aug 21;15(8):512. doi: 10.3390/toxins15080512.
78. Xu J, Li Y, Yang X, et al. Quercetin inhibited LPS-induced cytokine storm by interacting with the AKT1-FoxO1 and Keap1-Nrf2 signaling pathway in macrophages. Sci Rep. 2024 Sep 8;14(1):20913. doi: 10.1038/s41598-024-71569-y. Erratum in: Sci Rep. 2024 Nov 12;14(1):27708. doi: 10.1038/s41598-024-78855-9.
79. Serhiyenko VA, Serhiyenko AA. Diabetes mellitus and congestive heart failure. International journal of endocrinology (Ukraine). 2022;18(1):57-69. Ukrainian. doi: 10.22141/2224-0721.18.1.2022.1146.
80. Adamu A, Li S, Gao F, Xue G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future the–rapeutic targets. Front Aging Neurosci. 2024 Apr 12;16:1347987. doi: 10.3389/fnagi.2024.1347987.
81. Chiang MC, Tsai TY, Wang CJ. The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms. Int J Mol Sci. 2023 Mar 28;24(7):6328. doi: 10.3390/ijms24076328.
82. Deepika, Maurya PK. Health Benefits of Quercetin in Age-Related Diseases. Molecules. 2022 Apr 13;27(8):2498. doi: 10.3390/molecules27082498.
83. Cui Z, Zhao X, Amevor FK, et al. Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. Front Immunol. 2022 Jul 22;13:943321. doi: 10.3389/fimmu.2022.943321.
84. González I, Lindner C, Schneider I, Diaz E, Morales MA, Rojas A. Emerging and multifaceted potential contributions of polyphenols in the management of type 2 diabetes mellitus. World J Diabetes. 2024 Feb 15;15(2):154-169. doi: 10.4239/wjd.v15.i2.154.
85. Choy KW, Murugan D, Leong XF, Abas R, Alias A, Mustafa MR. Flavonoids as Natural Anti-Inflammatory Agents Targeting Nuclear Factor-Kappa B (NFκB) Signaling in Cardiovascular Diseases: A Mini Review. Front Pharmacol. 2019 Oct 31;10:1295. doi: 10.3389/fphar.2019.01295.
86. Dai W, Qiao X, Fang Y, et al. Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct Target Ther. 2024 Nov 26;9(1):332. doi: 10.1038/s41392-024-02039-0.
87. Long Y, Mao C, Liu S, Tao Y, Xiao D. Epigenetic modifications in obesity-associated diseases. MedComm (2020). 2024 Feb 24;5(2):e496. doi: 10.1002/mco2.496.
88. Spínola V, Llorent-Martínez EJ, Castilho PC. Inhibition of α-amylase, α-glucosidase and pancreatic lipase by phenolic compounds of Rumex maderensis (Madeira sorrel). Influence of simulated gastrointestinal digestion on hyperglycaemia-related damage linked with aldose reductase activity and protein glycation. LWT. 2020;118:108727. doi: 10.1016/j.lwt.2019.108727.
89. Gong L, Feng D, Wang T, Ren Y, Liu Y, Wang J. Inhibitors of α-amylase and α-glucosidase: Potential linkage for whole cereal foods on prevention of hyperglycemia. Food Sci Nutr. 2020 Nov 4;8(12):6320-6337. doi: 10.1002/fsn3.1987.
90. Ansari P, Choudhury ST, Seidel V, et al. Therapeutic Potential of Quercetin in the Management of Type-2 Diabetes Mellitus. Life (Basel). 2022 Jul 28;12(8):1146. doi: 10.3390/life12081146.
91. Liu PK, Chi YC, Chang YC, et al. Quercetin attenuates high glucose-induced VEGFA expression in ARPE-19 cells by inhibiting ROS generation, p38 MAPK phosphorylation, and NF-κB activation. Sci Rep. 2026 Jan 10;16(1):4987. doi: 10.1038/s41598-026-35409-5.
92. Guo YL, Niu WJ, Jiao HR, et al. Crosstalk between oxidative stress and inflammatory pathways: Natural therapeutic approaches for diabetic wound healing. World J Diabetes. 2025 Nov 15;16(11):111400. doi: 10.4239/wjd.v16.i11.111400.
93. Hosseini A, Razavi BM, Banach M, Hosseinzadeh H. Quercetin and metabolic syndrome: A review. Phytother Res. 2021 Oct;35(10):5352-5364. doi: 10.1002/ptr.7144.
94. Shabbir U, Rubab M, Daliri EB, Chelliah R, Javed A, Oh DH. Curcumin, Quercetin, Catechins and Metabolic Diseases: The Role of Gut Microbiota. Nutrients. 2021 Jan 12;13(1):206. doi: 10.3390/nu13010206. PMID: 33445760; PMCID: PMC7828240.
95. Ferenczyova K, Kalocayova B, Bartekova M. Potential Implications of Quercetin and its Derivatives in Cardioprotection. Int J Mol Sci. 2020 Feb 26;21(5):1585. doi: 10.3390/ijms21051585.
96. Mirza MA, Mahmood S, Hilles AR, et al. Quercetin as a Therapeutic Product: Evaluation of Its Pharmacological Action and Clinical Applications — A Review. Pharmaceuticals (Basel). 2023 Nov 20;16(11):1631. doi: 10.3390/ph16111631.
97. Michala AS, Pritsa A. Quercetin: A Molecule of Great Bioche–mical and Clinical Value and Its Beneficial Effect on Diabetes and Cancer. Diseases. 2022 Jun 29;10(3):37. doi: 10.3390/diseases10030037.
98. Ostadmohammadi V, Milajerdi A, Ayati E, Kolahdooz F, Asemi Z. Effects of quercetin supplementation on glycemic control among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2019 May;33(5):1330-1340. doi: 10.1002/ptr.6334.
99. Gregório BM, De Souza DB, de Morais Nascimento FA, Pereira LM, Fernandes-Santos C. The potential role of antioxidants in metabolic syndrome. Curr Pharm Des. 2016;22(7):859-869. doi: 10.2174/1381612822666151209152352.
100. Noshadi N, Bonyadian A, Hojati A, et al. The effect of quercetin supplementation on the components of metabolic syndrome in adults: A systematic review and dose-response meta-analysis of randomized controlled trials. 2025. J Funct Foods. 2025;115:106175. doi: 10.1016/j.jff.2024.106175.
101. Gouveia HJCB, Urquiza-Martínez MV, Manhães-de-Castro R, et al. Effects of the treatment with flavonoids on metabolic syndrome components in humans: A systematic review focusing on mechanisms of action. Int J Mol Sci. 2022 Jul 28;23(15):8344. doi: 10.3390/ijms23158344.
102. Hu Q, Qu C, Xiao X, et al. Flavonoids on diabetic nephro–pathy: advances and therapeutic opportunities. Chin Med. 2021 Aug 7;16(1):74. doi: 10.1186/s13020-021-00485-4.
103. Yan L, Vaghari-Tabari M, Malakoti F, et al. Quercetin: an effective polyphenol in alleviating diabetes and diabetic complications. Crit Rev Food Sci Nutr. 2023;63(28):9163-9186. doi: 10.1080/10408398.2022.2067825.
104. Zhang L, Xu LY, Tang F, et al. New perspectives on the the–rapeutic potential of quercetin in non-communicable diseases: Targeting Nrf2 to counteract oxidative stress and inflammation. J Pharm Anal. 2024 Jun;14(6):100930. doi: 10.1016/j.jpha.2023.12.020.
105. Mantadaki AE, Linardakis M, Tsakiri M, et al. Benefits of Quercetin on Glycated Hemoglobin, Blood Pressure, PiKo-6 Readings, Night-Time Sleep, Anxiety, and Quality of Life in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. J Clin Med. 2024 Jun 15;13(12):3504. doi: 10.3390/jcm13123504.
106. Yang DK, Kang HS. Anti-Diabetic Effect of Cotreatment with Quercetin and Resveratrol in Streptozotocin-Induced Diabetic Rats. Biomol Ther (Seoul). 2018 Mar 1;26(2):130-138. doi: 10.4062/biomolther.2017.254.
107. Dash UC, Bhol NK, Swain SK, et al. Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications. Acta Pharm Sin B. 2025 Jan;15(1):15-34. doi: 10.1016/j.apsb.2024.10.004.
108. Xu YH, Xu JB, Chen LL, Su W, Zhu Q, Tong GL. Protective mechanisms of quercetin in neonatal rat brain injury induced by hypoxic-ischemic brain damage (HIBD). Food Sci Nutr. 2023 Oct 13;11(12):7649-7663. doi: 10.1002/fsn3.3684.
109. Bellavite P. Neuroprotective potentials of flavonoids: expe–rimental studies and mechanisms of action. Antioxidants (Basel). 2023 Jan 27;12(2):280. doi: 10.3390/antiox12020280.
110. Zhao X, Wang J, Deng Y, et al. Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism. Phytother Res. 2021 Sep;35(9):4727-4747. doi: 10.1002/ptr.7104.
111. Grewal AK, Singh TG, Sharma D, et al. Mechanistic insights and perspectives involved in neuroprotective action of quercetin. Biomed Pharmacother. 2021 Aug;140:111729. doi: 10.1016/j.biopha.2021.111729.